The stock of uniQure N.V. (QURE) has seen a -7.44% decrease in the past week, with a -28.45% drop in the past month, and a 34.22% flourish in the past quarter. The volatility ratio for the week is 6.39%, and the volatility levels for the past 30 days are at 8.68% for QURE. The simple moving average for the last 20 days is -14.10% for QURE stock, with a simple moving average of 11.28% for the last 200 days.
Is It Worth Investing in uniQure N.V. (NASDAQ: QURE) Right Now?
The 36-month beta value for QURE is at 0.97. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for QURE is 44.92M, and currently, shorts hold a 8.50% of that float. The average trading volume for QURE on August 14, 2024 was 2.87M shares.
QURE) stock’s latest price update
uniQure N.V. (NASDAQ: QURE)’s stock price has decreased by -6.39 compared to its previous closing price of 7.04. However, the company has seen a -7.44% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-06 that uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington’s Disease, leading to a significant stock price increase. The company has aggressively restructured to extend its cash runway, focusing on AMT-130 development with confidence in its success. Despite risks, including potential negative trial data, its strong balance sheet and upcoming catalysts make it possible for QURE stock to reach $15 by year-end.
Analysts’ Opinion of QURE
Many brokerage firms have already submitted their reports for QURE stocks, with Goldman repeating the rating for QURE by listing it as a “Neutral.” The predicted price for QURE in the upcoming period, according to Goldman is $8 based on the research report published on February 29, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see QURE reach a price target of $10, previously predicting the price at $52. The rating they have provided for QURE stocks is “Neutral” according to the report published on December 19th, 2023.
UBS gave a rating of “Buy” to QURE, setting the target price at $40 in the report published on March 17th of the previous year.
QURE Trading at 3.02% from the 50-Day Moving Average
After a stumble in the market that brought QURE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.94% of loss for the given period.
Volatility was left at 8.68%, however, over the last 30 days, the volatility rate increased by 6.39%, as shares sank -22.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.64% upper at present.
During the last 5 trading sessions, QURE fell by -7.44%, which changed the moving average for the period of 200-days by +13.23% in comparison to the 20-day moving average, which settled at $7.58. In addition, uniQure N.V. saw -2.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QURE starting from Abi-Saab Walid, who sale 1,447 shares at the price of $4.36 back on Jun 26 ’24. After this action, Abi-Saab Walid now owns 115,253 shares of uniQure N.V., valued at $6,309 using the latest closing price.
CALOZ PIERRE, the Chief Operating Officer of uniQure N.V., sale 2,936 shares at $4.81 during a trade that took place back on Jun 17 ’24, which means that CALOZ PIERRE is holding 115,707 shares at $14,122 based on the most recent closing price.
Stock Fundamentals for QURE
Current profitability levels for the company are sitting at:
- -8.89 for the present operating margin
- -0.15 for the gross margin
The net margin for uniQure N.V. stands at -10.28. The total capital return value is set at -0.38. Equity return is now at value -126.41, with -34.02 for asset returns.
Based on uniQure N.V. (QURE), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at -0.2. The debt to equity ratio resting at 5.38. The interest coverage ratio of the stock is -1190.26.
Currently, EBITDA for the company is -251.41 million with net debt to EBITDA at -1.07. When we switch over and look at the enterprise to sales, we see a ratio of 20.38. The receivables turnover for the company is 3.53for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.36.
Conclusion
In conclusion, uniQure N.V. (QURE) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
